Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05914766 · ClinicalTrials.gov registry record · NA

An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer

A NA study of Rectal Cancer and Self Efficacy, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
2
Study locations

NCT05914766 is a NA study of Rectal Cancer and Self Efficacy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05914766, a NA study of Rectal Cancer and Self Efficacy, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
2
Study locations

Study Summary

The aim of this study is to evaluate the feasibility and acceptability of conducting a randomized trial of a brief psychoeducational intervention versus enhanced usual care for patients with locally advanced rectal cancer who are initiating neoadjuvant multimodality treatment.

Interventions

  • OTHER Enhanced usual care
  • BEHAVIORAL PATHWAYS

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-09-21
Est. Completion 2028-12
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT05914766

The ClinicalTrials.gov registry entry for NCT05914766 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Rectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enhanced usual care is the first listed.

NCT05914766 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05914766 about?

NCT05914766 is a clinical study titled "An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer". The aim of this study is to evaluate the feasibility and acceptability of conducting a randomized trial of a brief psychoeducational intervention versus enhanced usual care for patients with locally advanced rectal cancer who are initiating neoadjuvant multimodality treatment.

What is the current status of trial NCT05914766?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2023-09-21. Estimated completion is 2028-12.

What conditions does trial NCT05914766 study?

This clinical trial studies the following conditions: Rectal Cancer, Self Efficacy.

What interventions are being tested in trial NCT05914766?

The interventions under investigation include: Enhanced usual care (OTHER), PATHWAYS (BEHAVIORAL).

Who is sponsoring clinical trial NCT05914766?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05914766 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.